Matheson recently advised the Ireland Strategic Investment Fund on its equity investment in Mainstay Medical International plc (“Mainstay”). Mainstay raised a total of approximately €30 million from the Ireland Strategic Investment Fund, existing investors and new investors.
Mainstay is a medical device company focused on bringing to market an innovative implantable neurostimulation system, ReActiv8, for people with disabling Chronic Low Back Pain. The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States, Australia, Germany and the Netherlands, and is listed on the regulated market of the Euronext Paris and the ESM of the Irish Stock Exchange.
Speaking today George Brady, Corporate Partner at Matheson said “we are delighted to have been able to support the Ireland Strategic Investment Fund on this investment”.
The Matheson team was led by George Brady with support from a team of specialists in other areas across the firm.